



Theratechnologies Unveils New Positive Data For Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers

May 15, 2020

Significant inhibition of vasculogenic mimicry observed with TH1902 and TH1904

New peptide-curcumin conjugate, TH1901, shows 100 times greater anti-cancer cell proliferation activity than unconjugated curcumin in vitro

Results to be presented at American Association for Cancer Research (AACR) Virtual Annual Meeting II

Montreal, Canada – May 15, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced new positive results for its investigational Sortilin (SORT1) targeting peptide-drug conjugates (PDCs) which will be presented in three posters during AACR's virtual annual meeting II on June 22, 2020.

"We are very pleased with the results being presented at AACR. The strong activity of our technology against various cancers is very promising. Furthermore, it has shown a significant impact on vasculogenic mimicry, a process which is known to be associated with treatment resistance, tumor progression and poorer prognosis for patients", said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies.